-+ 0.00%
-+ 0.00%
-+ 0.00%
IDEAYA Biosciences (IDYA) Swung To A Third Quarter Loss, Is The Undervaluation Case Intact?
Share
Listen to the news

IDEAYA Biosciences (IDYA) just posted third quarter results that showed revenue of US$10.24 million and a swing from profit to a US$125.75 million loss compared with last year.

IDEAYA Biosciences shares closed at US$31.83, with the 1-day and 7-day share price returns of 1.08% and 1.89% sitting against a 30-day and 90-day share price decline of 6.0% and 12.31%. The 5-year total shareholder return of 37.08% points to momentum that has built over a longer horizon, even as recent earnings and the new US$94.92 million shelf registration have shifted the focus back onto risk and future funding needs.

Compare how IDEAYA Biosciences fits alongside hand picked oncology and biotech peers by scanning 31 resilient stocks with low risk scores that aim to balance downside risk with long term potential.

IDEAYA Biosciences has built a substantial precision oncology pipeline, yet the latest quarterly loss and potential equity issuance now throw a sharper spotlight on one thing: Are investors paying a fair price for that platform today?

Most Popular Narrative: 40% Undervalued

On the analyst consensus Narrative on Simply Wall St, IDEAYA Biosciences screens as undervalued, with a fair value of $52.75 versus the last close at $31.83. This places most of the weight on pipeline execution rather than current losses.

The main factor that needs to go right is successful execution on multiple registrational programs, including darovasertib in uveal melanoma and IDE849 in extensive-stage small-cell lung cancer, while managing trial pivots and competitive pressure in DLL3 therapies.

See why 1 investors see IDEAYA Biosciences as 40% undervalued.

Result: Fair Value of $52.75 (UNDERVALUED)

Still, the IDEAYA Biosciences story can change quickly if regulatory timelines on darovasertib slip or if IDE849 struggles to differentiate in a crowded DLL3 field.

Find out about the key risks to this IDEAYA Biosciences narrative.

Another View: SWS DCF Flags IDEAYA Biosciences As Expensive

Analyst targets lean bullish on IDEAYA Biosciences, yet the Simply Wall St DCF model points in the opposite direction. At $31.83, the stock trades well above an estimated future cash flow value of $6.80, which suggests limited support from modeled cash generation. Which lens do you trust more?

For a closer look at the assumptions behind that cash flow based estimate, including discount rates and scenario ranges, Look into how the SWS DCF model arrives at its fair value.

IDYA Discounted Cash Flow as at Nov 2026
IDYA Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on IDEAYA Biosciences so far? The data is on the table right now. Move quickly, review the full picture, and weigh both the upside and the downside with 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond IDEAYA Biosciences?

If IDEAYA Biosciences has sharpened your focus on risk and reward, do not stop here. Broadening your idea search can quickly change the quality of your watchlist.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending